MS Virtual 2020

COVID-19 and MS

Risk of COVID-19 not increased in MS patients

Conference

MS Virtual 2020

25 November, 2020 17:10

Age and EDSS are risk factors for severe COVID-19

Trial

Cohort study, COVISEP

Conference

MS Virtual 2020

25 November, 2020 17:09

Anti-CD20 DMTs associated with worse COVID-19 outcomes

Conference

MS Virtual 2020

25 November, 2020 17:09

Black MS patients have poorer COVID-19 outcomes

Trial

COViMS

Conference

MS Virtual 2020

25 November, 2020 17:08

Biomarkers

Gut bacteria associated with relapse in paediatric-onset MS

Conference

MS Virtual 2020

25 November, 2020 17:08

Predictive value of CSF Aβ and tau proteins in MS

Conference

MS Virtual 2020

25 November, 2020 17:08

Serum NfL as biomarker for suboptimal treatment response

Trial

Cohort study, Swiss MS

Conference

MS Virtual 2020

25 November, 2020 17:07

Interrupting DMT due to pregnancy increases NfL levels

Conference

MS Virtual 2020

25 November, 2020 17:06

Predicting autoimmunity in patients treated with alemtuzumab

Conference

MS Virtual 2020

25 November, 2020 17:06

Serum glial fibrillary acidic protein predicts relapses in NMOSD

Conference

MS Virtual 2020

25 November, 2020 17:06

Assessing demyelination using myelin water imaging

Conference

MS Virtual 2020

25 November, 2020 17:06

Grey matter network measures predict disability and cognition

Trial

Phase 3, ASCEND

Conference

MS Virtual 2020

25 November, 2020 17:05

Lesion-specific perfusion levels affect myelin loss and repair

Conference

MS Virtual 2020

25 November, 2020 17:05

Treatment Strategies and Results

Management of progressive MS with approved DMT

Presented By

Prof. Xavier Montalban, Vall d'Hebron University Hospital, Spain

Trial

ASCEND, MS-SMART

Conference

MS Virtual 2020

25 November, 2020 17:01

Outcomes in patients on alemtuzumab with thyroid adverse events

Trial

CARE-MS

Conference

MS Virtual 2020

25 November, 2020 17:01

Safety and efficacy of dimethyl fumarate: 13 years of follow-up

Trial

ENDORSE, DEFINE, CONFIRM

Conference

MS Virtual 2020

25 November, 2020 17:00

Update on estimated PML risk related to fingolimod

Conference

MS Virtual 2020

25 November, 2020 17:00

Less thalamic atrophy in patients initiating ocrelizumab earlier

Conference

MS Virtual

25 November, 2020 16:59

No new safety signals in ofatumumab open-label data

Trial

ALITHIOS, ASCLEPIOS I, ASCLEPIOS II, APLIOS

Conference

MS Virtual 2020

25 November, 2020 16:57

Long-term safety and efficacy of ozanimod in RMS

Trial

Phase 3, DAYBREAK

Conference

MS Virtual 2020

25 November, 2020 16:57

Low-dose rituximab as effective as high-dose, but safer

Conference

MS Virtual 2020

25 November, 2020 16:57

TERIKIDS trial extension of teriflunomide in paediatric MS

Trial

Phase 3, TERIKIDS

Conference

MS Virtual 2020

25 November, 2020 16:56

Teriflunomide improves satisfaction versus prior DMT regardless of age

Trial

Phase 4, Teri-PRO

Conference

MS Virtual 2020

25 November, 2020 16:55

Safety and efficacy of cladribine, glatiramer acetate, and more

Trial

CLASSIC-MS, OPTIMUM

Conference

MS Virtual 2020

25 November, 2020 16:55

Novel Treatment Directions

Functional potential of gut microbiome in paediatric MS

Conference

MS Virtual 2020

25 November, 2020 16:49

Modulating BTK-dependent inflammatory signalling in microglia

Conference

MS Virtual 2020

25 November, 2020 16:49

Therapeutic potential of anti-MOSPD2 monoclonal antibodies

Conference

MS Virtual 2020

25 November, 2020 16:49

Masitinib: a first-in-class TKI as treatment of progressive MS

Trial

AB07002

Conference

MS Virtual 2020

25 November, 2020 16:49

Gold nanocrystals may improve brain metabolic profile

Trial

REPAIR-MS, REPAIR-PD, VISIONARY-MS

Conference

MS Virtual 2020

25 November, 2020 16:48

Retinoid-X receptor agonist promotes remyelination

Conference

MS Virtual 2020

25 November, 2020 16:48

Neuromyelitis Optica Spectrum Disorders

Miscellaneous Topics